Deandra Maharani Widiatmaja, Deandra and Alyaa Ulaa Dhiya Ul Haq, Alyaa and Dinda Dwi Purwati, Dinda and Arifa Mustika, Arifa The Potency Of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) As Adjuvant Therapy For Chronic Kidney Disease. World Journal of Advanced Research and Reviews, 13 (1). pp. 273-279. ISSN 2581-9615

	Text (Artikel) 13 artikel.pdf Download (1MB)
	Text (Turnitin) 13 turnitin.pdf Download (1MB)
	Text (Kualitas Karil & Kesesuaian Bidang Ilmu) 13 karil.pdf Download (580kB)
	Text (Bukti Korespondensi) 13. koresponden the potency of.pdf Download (432kB)

Abstract

Abstract Chronic kidney disease (CKD) prevalence keeps increasing worldwide and being particular concern due to its morbidity and mortality. However, current CKD therapy are known to be economically costly and not necessarily provide better outcomes. Epigallocatechin gallate (EGCG) is one of the substances that widely studied as perspective therapeutic agents of CKD due to its anti-inflammatory, antioxidant, and enhancing mitochondrial function ability. However, the use of EGCG is limited to low bioavailability and poor pharmacokinetic profile. Encapsulation of EGCG with PLGA is expected to increase the efficacy of EGCG especially for its use as the kidney protective agent and optimize therapy of CKD. Thus, this study aims to analyze the potency of PLGA-encapsulated EGCG as the adjuvant therapy for CKD. This study was a narrative review summarizes studies related to current adjuvant therapy of CKD. EGCG has beneficial effects in reducing pro-inflammatory cytokines among chronic kidney disease. EGCG also can increase scavenging of free radicals to decrease reactive oxygen species. EGCG is known to enhance mitochondrial function and increase mitochondrial protection to prevent apoptosis in various kidney diseases. Combination of PLGA encapsulation with EGCG has a beneficial effect in improving the delivery, bioavailability, stability, and the pharmacokinetic profile of EGCG. PLGA-encapsulated EGCG also provides a better therapeutic effect on preventing and decreasing progression of kidney damage. Finally, this study concluded that combination of PLGA-encapsulated EGCG has a potency as the adjuvant therapy of CKD.

Actions (login required)

View Item